scholarly journals Positron Emission Tomography/Computed Tomography Identification of Clear Cell Renal Cell Carcinoma: Results From the REDECT Trial

2013 ◽  
Vol 31 (2) ◽  
pp. 187-194 ◽  
Author(s):  
Chaitanya R. Divgi ◽  
Robert G. Uzzo ◽  
Constantine Gatsonis ◽  
Roman Bartz ◽  
Silke Treutner ◽  
...  
Keyword(s):  
Computed Tomography ◽  
Positron Emission Tomography ◽  
Renal Cell Carcinoma ◽  
Clear Cell ◽  
Emission Tomography ◽  
Average Sensitivity ◽  
Cell Renal Cell Carcinoma ◽  
Renal Masses ◽  
Positron Emission ◽  
Pet Ct

Purpose A clinical study to characterize renal masses with positron emission tomography/computed tomography (PET/CT) was undertaken. Patients and Methods This was an open-label multicenter study of iodine-124 (124I) -girentuximab PET/CT in patients with renal masses who were scheduled for resection. PET/CT and contrast-enhanced CT (CECT) of the abdomen were performed 2 to 6 days after intravenous 124I-girentuximab administration and before resection of the renal mass(es). Images were interpreted centrally by three blinded readers for each imaging modality. Tumor histology was determined by a blinded central pathologist. The primary end points—average sensitivity and specificity for clear cell renal cell carcinoma (ccRCC)—were compared between the two modalities. Agreement between and within readers was assessed. Results 124I-girentuximab was well tolerated. In all, 195 patients had complete data sets (histopathologic diagnosis and PET/CT and CECT results) available. The average sensitivity was 86.2% (95% CI, 75.3% to 97.1%) for PET/CT and 75.5% (95% CI, 62.6% to 88.4%) for CECT (P = .023). The average specificity was 85.9% (95% CI, 69.4% to 99.9%) for PET/CT and 46.8% (95% CI, 18.8% to 74.7%) for CECT (P = .005). Inter-reader agreement was high (κ range, 0.87 to 0.92 for PET/CT; 0.67 to 0.76 for CECT), as was intrareader agreement (range, 87% to 100% for PET/CT; 73.7% to 91.3% for CECT). Conclusion This study represents (to the best of our knowledge) the first clinical validation of a molecular imaging biomarker for malignancy. 124I-girentuximab PET/CT can accurately and noninvasively identify ccRCC, with potential utility for designing best management approaches for patients with renal masses.

Positron Emission Tomography/Computed Tomography with 89Zr-girentuximab Can Aid in Diagnostic Dilemmas of Clear Cell Renal Cell Carcinoma Suspicion

2018 ◽  
Vol 74 (3) ◽  
pp. 257-260 ◽  
Author(s):  
Marlène C.H. Hekman ◽  
Mark Rijpkema ◽  
Erik H. Aarntzen ◽  
Sasja F. Mulder ◽  
Johan F. Langenhuijsen ◽  
...  
Keyword(s):  
Computed Tomography ◽  
Positron Emission Tomography ◽  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Clear Cell ◽  
Emission Tomography ◽  
Cell Renal Cell Carcinoma ◽  
Positron Emission

scholarly journals 18F-FDG positron emission tomography combined with computed tomography in renal cell carcinoma diagnostics

2021 ◽  
Vol 16 (4) ◽  
pp. 160-169
Author(s):  
V. S. Ilyakov ◽  
Artem Pronin ◽  
A. I. Mikhaylov ◽  
A. V. Parnas ◽  
Nadezhda Meshcheriakova ◽  
...  
Keyword(s):  
Computed Tomography ◽  
Positron Emission Tomography ◽  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Fdg Pet ◽  
Renal Cell ◽  
Emission Tomography ◽  
Positron Emission ◽  
Pet Ct ◽  
Fdg Pet Ct

Positron emission tomography combined with computed tomography (PET/CT) is a method, capable of evaluation of not only structural, but also metabolic alterations in organs and tissues. 18F-fluorodeoxyglucose (18F-PDG) PET/CT is widely used in diagnostics of various malignant tumors, but its role in renal cell carcinoma (RCC) remains obscure.Despite its limited effectiveness in primary and differential diagnosis of RCC, PET/CT can be used to determine the grade of malignancy and the histological type of tumor. According to various authors, 18F-FDG standardized uptake value (SUV) of a renal neoplasm can serve as an independent prognostic factor of overall survival.18F-FDG PET/CT is widely used to detect local recurrence and metastatic lesions in various neoplastic processes. Numerous studies confirm the high efficiency of PET/CT in detection of metastases and recurrence discernment for RCC.The ability to assess the metabolic activity of neoplastic foci using PET/CT may allow for evaluation of RCC therapy effectiveness, which is confirmed by clinical studies of various targeted therapy agents, such as tyrosine kinase inhibitors, mammalian target of rapamycin inhibitors, and monoclonal antibodies.Thus, there is growing evidence that 18F-FDG PET/CT is a useful tool in diagnostics of RCC.

The Potential Value of Hybrid Positron Emission Tomography/Dual-Source Computed Tomography Imaging in Coronary Bypass Surgery

2011 ◽  
Vol 14 (5) ◽  
pp. 283 ◽  
Author(s):  
Andre Plass ◽  
Maximilian Y. Emmert ◽  
Oliver Gaemperli ◽  
Hatem Alkadhi ◽  
Philipp Kaufmann ◽  
...  
Keyword(s):  
Computed Tomography ◽  
Positron Emission Tomography ◽  
Coronary Artery ◽  
Coronary Angiography ◽  
Myocardial Perfusion ◽  
Predictive Value ◽  
Bypass Surgery ◽  
Emission Tomography ◽  
Positron Emission ◽  
Pet Ct

<p><b>Background:</b> We evaluated how comprehensive assessment of coronary artery lesions and their hemodynamic relevance by means of hybrid positron emission tomography (PET) and computed tomography (CT) imaging would affect decision-making in coronary artery bypass surgery (CABG), compared with using invasive coronary angiography (ICA) alone.</p><p><b>Methods:</b> After undergoing ICA, 27 patients (21 men and 6 women; mean SD age, 66 � 10 years) planned for cardiac surgery were scheduled for myocardial perfusion stress/rest evaluation with [13N]ammonia PET and CT coronary angiography. Only ICA was available to the surgeon. Postoperatively, the performed CABG was compared with the hypothetical strategy based on hybrid PET/CT findings (regional coronary flow reserve [CFR], myocardial perfusion defects). Procedures included CABG (n = 18) alone, CABG combined with valve replacement (n = 6), and CABG combined with isolated valve replacement (n = 3). A total of 56 bypass grafts (28 venous and 28 arterial) and 66 distal anastomoses were placed.</p><p><b>Results:</b> CT evaluation showed 93% concordance (66/71) with ICA regarding significant stenoses, with sensitivity, specificity, positive predictive value, and negative predictive value of 93.1%, 98.7%, 94.4%, and 98.4%, respectively. In the PET scan, 16 patients had 1 ischemic region, and 12 patients had 1 scar region, including 5 patients who presented with mixed conditions (scar and ischemia). One patient had a completely normal myocardium. Compared with the performed surgery, PET/CT fusion evaluation showed that of the performed anastomoses, 48% had documented ischemia (with a CFR <2 in 86%), 38% were nonischemic (although a CFR value <2 was found in 78%), and 14% had scar tissue (fixed perfusion defect).</p><p><b>Conclusions:</b> Although <50% of bypasses were placed to areas with myocardial ischemia, the CFR was low in the majority of nonischemic regions, a finding that may have important prognostic relevance. PET/CT fusion imaging could potentially influence planning for CABG and provide incremental prognostic information.</p>

Sign in / Sign up

Export Citation Format

Share Document